Does microperimetry have a role in monitoring visual function in patients with Behçet uveitis? Authors: Mehmet Fatih Kağan Değirmenci, F Nilüfer Yalçındağ Published: 2024 ABSTRACT AbstractBackgroundTo evaluate the change in time in visual acuity, central macular thickness (CMT), and microperimetry (MP) findings in Behçet uveitis (BU) patients who were in remission with maintenance therapy.MethodsThis single center, retrospective, observational cohort study included twenty-five eyes of 25 patients with BU who were in remission during maintenance therapy. Best corrected visual acuity (BCVA), CMT, macular integrity index, average threshold, and fixation stabilities (P1 and P2) evaluated at six-month intervals were recorded. The changes in time were statistically analyzed. Paired samples t-test was used for normally distributed data and Wilcoxon rank test was performed for non-normally distributed data.ResultsThe mean BCVA and CMT showed no significant changes after six months. Although the mean macular integrity index decreased and the mean fixation stabilities increased after six months, these findings were not statistically significant. The mean average threshold was 16.8 dB at baseline and it increased significantly to 19.3 dB in the sixth month (p < 0.001).ConclusionsThe results of our study suggest that although visual acuity and CMT showed no change in patients with Behçet uveitis receiving maintenance therapy, MP could detect an improvement in macular function.Keywords: Behçet uveitis, Optical coherence tomography, Microperimetry, Average threshold, Visual function Background Behçet disease (BD) is a chronic multisystemic inflammatory disorder without a known etiology [1]. Eye is the most commonly involved essential organ and presentation is typically relapsing remitting panuveitis and retinal vasculitis [2]. The manifestations of Behçet uveitis (BU) were reviewed in many studies. Posterior uveitis and sight-threatening complications such as cystoid macular edema, macular atrophy, macular ischemia, macular hole, and epiretinal membrane (ERM) are the leading causes of visual impairment in BU [1, 3]. Changes in visual acuity (VA) and optical coherence tomography (OCT) findings are the most widely used outcome measures for monitoring the status of many ophthalmological diseases in daily practice and research. However, these two variables are not always sufficient for reflecting visual function, disease activity, and assessing treatment outcomes, especially in patients with low VA and chronic complications. Therefore, it was hypothesized that a more convenient technique for assessing visual function would be beneficial. The utilisation of microperimetry, a diagnostic modality that assesses visual function through the quantitative evaluation of the macular visual field [4], may offer a potential avenue for further investigation in this context. This study aimed to evaluate the changes in time, in terms of VA, central macular thickness (CMT), and MP findings, among patients with BU who were in remission with systemic maintenance therapy. Methods This retrospective study enrolled 25 BU patients on systemic therapy with clinically and angiographically inactive disease for at least 6 months. One eye of each patient was randomly selected and 25 eyes were included in the study for statistical analysis. This study was approved by the Institutional Review Board and was performed in accordance with the tenets of the Declaration of Helsinki. Patients who met the classification criteria of the International Study Group criteria [5] and/or International Criteria for BD [6] were retrospectively analyzed in the study. Patients with 6-month intervals of detailed eye examination records, spectral domain (SD)-OCT, and MP tests were recruited for this study. The exclusion criteria were as follows: active inflammation, optic atrophy, advanced cataract or any media opacity capable of compromising vision or image quality, macular edema, a history of retinal surgery, presence of comorbid ocular disorders such as glaucoma or retinal vascular diseases (diabetic retinopathy and retinal vascular occlusive diseases). Demographic data of the patients (age and sex), treatment modalities, and duration of uveitis and treatment were obtained from patient files. Best corrected visual acuity (BCVA) data was converted to logarithm of the minimum angle of resolution (logMAR) units for statistical analysis. SD-OCT images obtained using the RTVue XR Avanti system (Optovue, Inc., Fremont, CA, USA) were analyzed for central macular thickness (CMT) and the presence of macular atrophy (central macular thickness < 200 μm), retinal pigment epithelium (RPE) atrophy or ERM. All participants were subjected to MP test in both eyes. The Macular Integrity Assessment Microperimeter (MAIA) MP equipment (CentreVue, Padova, Italy) was used to determine the macular integrity index, average threshold, and fixation stability (P1 and P2) (Fig. 1). The macular integrity index, a unique parameter of MAIA MP, is a numerical value that indicates how likely a patient’s response is to be normal, suspicious or abnormal compared to an age-matched norm. The fixation stability (P1 and P2) is defined as examining fixation losses along with recording fixation pattern. P1 and P2 are computed values and indicate the percentage of fixation points within circles of 2 and 4 degrees in diameter, respectively. The changes in ophthalmological examination findings, SD-OCT and MP findings within 6 months were statistically analyzed. The representative images of one of the patients, comprising coloured fundus photographs (upper left), fluorescein angiography images (middle left) and optical coherence tomography images (lower left), and the microperimetry test results (right), are shown (A, B, C and G are baseline findings and D, E, F and H are the sixth month findings) Statistical analysis All analyses were performed with SPSS for Windows version 20.0 (SPSS Inc., IBM, NY, USA). The normality of the data was determined by the Kolmogorov-Smirnov test. Paired samples t-test was used for normally distributed data and Wilcoxon rank test was performed for non-normally distributed data. A p-value < 0.05 was set for statistical significance. Results Of the 25 patients included in the study, 17 were male and 8 were female. The mean age of the patients was 30.3 ± 2.4 (range: 24–39) years. Twelve patients (48%) were taking interferon alpha-2a (subcutaneous injection), 7 patients (33.3%) were taking cyclosporine (oral) and 8 patients (32%) were taking azathioprine (AZA) (oral) monotherapy. Four patients (16%) were taking infliximab (intravenous injection) in combination with AZA. The median duration of uveitis and treatment of the patients were 29.6 months (range: 17–47 months) and 16.1 months (range: 10–32 months), respectively. The mean BCVAs were 0.42 ± 0.08 logMAR at baseline and 0.40 ± 0.06 logMAR in the sixth month. The increase in VA was not statistically significant (p = 0.58). None of the eyes had intraocular pressure (IOP) above the normal limit of 21 mmHg at both the baseline and 6-month follow-up examinations. There was no significant change in the mean IOP of the eyes after a 6-month period (18.2 ± 1.8 mmHg at baseline and 18.9 ± 1.6 mmHg at the sixth month, p = 0.09). While the mean CMT of the eyes was 215 ± 12.1 μm at baseline, it was 210.1 ± 10.2 μm in the sixth month (p = 0.41). At baseline, 12 (48%) of the eyes had macular atrophy, six (24.0%) of the eyes had ERM and five (20.0%) of the eyes had RPE atrophy. During the six-month evaluation, no changes were observed in these morphological findings. At the end of the six-month follow-up, no statistically significant change was observed in the macular integrity index (p = 0.13). It was 82.2 ± 6.5% at baseline and 78.9 ± 7.9% in the sixth month. Despite the increase in fixation stability observed during the 6-month follow-up, it was not statistically significant. The mean fixation stability values of P1 were 63.3 ± 4.6% at baseline and 65.1 ± 3.4% in the sixth month (p = 0.37). The mean values of P2 were 79.1 ± 5.1% at baseline and 83.7 ± 6% in the sixth month (p = 0.24). Among the MP findings, only the mean average threshold showed a statistically significant change. It increased from 16.8 ± 1.8 (range: 13.6–30.3) dB at baseline and to 19.3 ± 2.2 (range: 13.9–33.5) dB in the sixth month (p < 0.001). Additionally, the changes of the BCVA, CMT and MP results over time are illustrated in graphical form in Fig. 2. The change in best corrected visual acuity (BCVA), central macular thickness (CMT) and microperimetry (MP) test results are documented at six-month intervals are presented in graphics. Please note that p values showing the statistical significance of the changes in time are indicated just above the graphs Discussion In this study, we investigated patients with BU who were in remission with maintenance therapy, whether to assess the change in BCVA, CMT, and MP findings (macular integrity index, fixation stability, and average threshold) over time. We found an increase in average threshold value within six months, while BCVA, CMT, macular integrity index and fixation stability remained stable. In assessing the foveal function, VA is currently used in clinical practice. It is established that a considerable number of patients diagnosed with BU can suffer from irreversible visual impairment, despite the availability of effective treatment options [7, 8]. In a review, Ozyazgan et al. proposed a classification system for ophthalmic findings, differentiating between reversible and irreversible changes [9]. During the course of inflammation, irreversible changes occur slowly and continue to happen during remission. It would appear that VA is not a reliable indicator of visual function, especially in patients with irreversible ocular changes and poor VA. This situation leads us to look for new methods for the evaluation of visual function across the macula that will provide more indicative results than those obtained through VA. In our study, the patients were in remission therapy. The mean BCVA was 0.42 logMAR and showed no significant change after six months of maintenance treatment. VA seems to be preserved because intraocular inflammation was controlled and future complications were prevented. Spectral domain-optical coherence tomography is also useful for monitoring macular findings and changes which correlate visual capability of the patients with uveitis [10]. In a few studies, macular thickness has been investigated by SD-OCT in patients with uveitis without macular complications [11, 12]. These studies suggested that macular thickness measured by OCT can be used to monitor the disease activity of uveitis. No significant change in CMT was observed in the current study. Our results seem to be consistent with the previous studies. Because the patients in our study were already in remission with systemic treatment, no significant change in CMT was seen. Microperimetry is a non-invasive method used to analyze fixation and central retinal sensitivity. It provides detailed information on macular function even in patients with low VA. In recent years, MP is increasingly being used in the diagnosis and follow-up of retinal disorders such as age-related macular degeneration [13, 14], diabetic maculopathy [15–17], macular hole [18, 19], central serous chorioretinopathy [20, 21], Stargardt disease [22] and retinitis pigmentosa [23]. However, only a few studies analyzed MP changes in patients with uveitis. Roesel et al. [24] compared retinal thickness and MP findings with VA in uveitic macular edema. They concluded that both foveal thickness and MP findings were correlated with VA. In a study, Takeuchi et al. [25] investigated perimetric sensitivity by MP and retinal thickness by OCT in 20 patients with ocular BD. Although their patients were clinically inactive, all enrolled patients had diffuse dye leakage on fluorescein angiography. They found that perimetric sensitivity and retinal thickness decrease while the duration of uveitis increases. However, in our study, we enrolled patients with clinically and angiographically inactive disease and evaluated if there were any significant changes during maintenance therapy in BCVA, CMT, and MP findings. The macular integrity index and fixation stability obtained by MP were also stable after six months. However, it was observed that the average threshold increased significantly in the sixth month. Although there was much study evaluating functional changes during inactive uveitis, in a post hoc analysis of two clinical trials in which the changes in visual function and quality of life of patients with inactive intermediate, posterior and panuveitis were analysed after treatment, it was found that patient-reported visual function improved after treatment [26]. Another illustrative case report described an improvement in visual acuity and a restoration of photoreceptor layer on optical coherence tomography images of a patient with Behçet’s uveitis following treatment with infliximab [27]. In this context, it seems likely that there may be an increase in retinal sensitivity, although this is not reflected in visual acuity, even in patients with inactive uveitis during systemic treatment. Our study had limitations including a relatively small number of patients and short-time follow-up. However, the current study is important in terms of showing the 6-month MP follow-up results of patients with inactive BU. While BCVA, CMT, macular integrity index and fixation stability showed no change in a period of six months, the average threshold increased in inactive ocular Behçet patients who had maintenance therapy. Conclusion Our results showed that visual acuity and CMT showed no change in patients with BU receiving maintenance therapy over a six-month period. However, the average threshold revealed by MP showed a significant increment in these patients. This indicates that MP may serve as a valuable tool for identifying subtle alterations in macular functionality and monitoring visual status in BU during the maintenance phase of treatment. Further research with larger cohorts and longer-term follow-up is essential to determine the efficacy of MP in evaluating visual function in BU. Acknowledgements Not applicable. Abbreviations Azathioprine Best corrected visual acuity Behçet disease Behçet uveitis Central macular thickness Epiretinal membrane Intraocular pressure Microperimetry Optical coherence tomography Retinal pigment epithelium Spectral domain optical coherence tomography Visual acuity Author contributions Both authors performed eye examination of the patients and evaluated patients’ data. Statistical analyses was performed by MFKD. Both authors contributed in writing the manuscript, and read and approved the final manuscript. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Institutional Ethics Committee (Ankara University Faculty of Medicine, Ethics Committee) and written informed consent was obtained from the participants. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.